 Actinium Pharmaceuticals NYSEMKT: ATNM stock is gaining on Monday after posting positive results from a Phase 3 clinical trial. The point of this clinical trial was to determine the effectiveness of Iomab-B in treating patients suffering from Elderly Relapsed or Refractory AML. 